Azilect and Macular opacity - a phase IV clinical study of FDA data

Summary:

Macular opacity is reported only by a few people who take Azilect.

The phase IV clinical study analyzes which people take Azilect and have Macular opacity. It is created by eHealthMe based on reports of 7,387 people who have side effects while taking Azilect from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 02, 2023

7,387 people reported to have side effects when taking Azilect.
Among them, 1 person (0.01%) has Macular opacity.

What is Azilect?

Azilect has active ingredients of rasagiline mesylate. It is often used in parkinson's disease. eHealthMe is studying from 7,886 Azilect users for its effectiveness, alternative drugs and more.

What is Macular opacity?

Macular opacity (opaque macula) is found to be associated with 50 drugs and 30 conditions by eHealthMe.

Number of Azilect and Macular opacity reports submitted per year:

Gender of people who have Macular opacity when taking Azilect *:

female: 0.0 %
male: 100 %

Age of people who have Macular opacity when taking Azilect *:

Common drugs people take besides Azilect *:

Tobrex: 1 person, 100.00%
Tobradex: 1 person, 100.00%
Exforge: 1 person, 100.00%

Common side effects people have besides Macular opacity *:

Pupillary Reflex Impaired: 1 person, 100.00%
Conjunctivitis (pink eye): 1 person, 100.00%
Cataract (clouding of the lens inside the eye): 1 person, 100.00%
Atrophy (wasting away of a part of the body): 1 person, 100.00%

Common conditions people have *:

Stress And Anxiety: 1 person, 100.00%
High Blood Pressure: 1 person, 100.00%
Dry Eyes (lack of adequate tears): 1 person, 100.00%
Cerebral Infarction (less blood supply to brain resulting tissue damage): 1 person, 100.00%
Cataract (clouding of the lens inside the eye): 1 person, 100.00%
Anaesthesia: 1 person, 100.00%
Age-Related Macular Degeneration: 1 person, 100.00%
Acid Base Balance: 1 person, 100.00%

* Approximation only. Some reports may have incomplete information.

Do you take Azilect and have Macular opacity?

Check whether Macular opacity is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Hipoglisemi RB, "Rasagiline-Induced Hypoglycemia", , 2016 Jan .

Related studies

How severe was Macular opacity and when was it recovered:

Macular opacity in Azilect

Expand to all the drugs that have ingredients of rasagiline mesylate:

Macular opacity and drugs with ingredients of rasagiline mesylate

Alternative drugs to, pros and cons of Azilect:

Azilect (7,886 reports)

Common Azilect side effects:

Browse all side effects of Azilect:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Macular opacity treatments and more:

Macular opacity (28 reports)

COVID vaccines that are related to Macular opacity:

All the drugs that are associated with Macular opacity:

Macular opacity (50 drugs)

All the conditions that are associated with Macular opacity:

Macular opacity (30 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on rasagiline mesylate (the active ingredients of Azilect) and Azilect (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.